Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the

Oxygen Biotherapeutics Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attack and strokes. Oxycyte is the company’s perfluorocarbon (PFC) therapeutic oxygen carrier.

The company’s invention, called Vitavent, provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be used easily by a victim of a heart attack or stroke, who is still conscious, without the assistance of another. It also may be used by someone who cannot adequately perform CPR in order to assist someone who is unconscious.

By safely combining Oxycyte and oxygen, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim’s lung an oxygen load that is 50 times greater than

Yesterday, Oxygen Biotherapeutics, Inc. announced that the company has received approval from Israel’s Ministry of Health to begin a Phase II-b clinical trial for use of Oxycyte(R), a perfluorocarbon therapeutic oxygen carrier, in traumatic brain injuries. With four centers in Israel, the clinical trial is part of a larger study that also includes seven trial centers in Switzerland.

The company has named the study “Safety and Tolerability of Oxycyte in Patients with Traumatic Brain Injury” or “STOP TBI.” The dose escalation trial aims to discover the lowest possible dose of Oxycyte that provides clinical benefit in traumatic brain injury while minimizing adverse effects. Dose levels of Oxycyte would start at 1.0 ml/kg body weight and escalate in steps to 2.0 ml/kg, and 3.0 ml/kg. Dose escalation will only occur after a favorable review of safety data by an independent Data Safety Monitoring Board.

Chris stern, company chairman and CEO, stated, “This

Oxygen Biotherapeutics, Inc. is a pharmaceutical company dedicated to oxygen therapies and continuous substrate monitoring. For those unfamiliar with oxygen therapies, it refers to products that mimic human blood’s oxygen transport ability. Oxygen therapeutics are in turn broken into two categories based on transport mechanism: perfluorocarbon based, and hemoglobin based.

The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and an implantable glucose sensor. Oxycyte®, once commercialized, may help patients recover from traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.

Yesterday the company announced that the animal studies conducted using rats given different doses of Oxycyte showed improved brain cognitive ability after brain trauma. The researchers found that injured animals treated with a dose of Oxycyte had significant improvement in ability to learn. The ability to learn and perform complex tasks (a maze)

Oxygen Biotherapeutics Inc. (OTCBB: OXBO) engages in marketing innovative pharmaceuticals and medical devices to monitor respiration in patients suffering from or associated with respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.

The company today announced it will submit an amended test protocol to the U.S. Food and Drug Administration, as well as in Canada, to cover the dose escalation studies of the company’s therapeutic oxygen carrier Oxycyte. The company plans on recruiting 40 traumatic brain injury (TBI) patients in each country to test the safety and efficacy of Oxycyte.

“Personally, I think that the extensive data we will collect in the dose escalation studies should be more than needed for proof-of-concept in both safety and efficacy. The advantage is that we should have the data we need much earlier, after each cohort of 10, rather than after 200 patients as it was previously planned. Another important

Oxygen Biotherapeutics, Inc. announced that a license agreement for its glucose biosensor technology has been reached with Glucometrics, Inc. The biosensor measures glucose levels in diabetes patients at accuracy levels higher than FDA standards require, a company news release states.

Glucometrics now has a license for all applications involving measurement and monitoring of glucose levels. In return, Oxygen Biotherapeutics receives stock in Glucometrics and royalties based on worldwide net revenues from products derived from the licensed technology.

“I am proud to announce this major milestone in our corporate history with our first-ever license agreement,” said OXBO Chairman and CEO Chris J. Stern. “With this agreement, the biosensor intellectual property can be developed to its full potential with the possibility of generating a future royalty stream for our shareholders.”

Stern said the company had prioritized the development of applications for Oxycyte and was not able to allocate enough resources for furthering its biosensor. Oxycyte

Oxygen Biotherapeutics, Inc. announced that a license agreement for its glucose biosensor technology has been reached with Glucometrics, Inc. The biosensor measures glucose levels in diabetes patients at accuracy levels higher than FDA standards require, a company news release states.

Glucometrics now has a license for all applications involving measurement and monitoring of glucose levels. In return, Oxygen Biotherapeutics receives stock in Glucometrics and royalties based on worldwide net revenues from products derived from the licensed technology.

“I am proud to announce this major milestone in our corporate history with our first-ever license agreement,” said OXBO Chairman and CEO Chris J. Stern. “With this agreement, the biosensor intellectual property can be developed to its full potential with the possibility of generating a future royalty stream for our shareholders.”

Stern said the company had prioritized the development of applications for Oxycyte and was not able to allocate enough resources for furthering its biosensor. Oxycyte

Oxygen Biotherapeutics, Inc. (OTCBB: OXBO) announced that they have a meeting scheduled for October with the Food and Drug Administration about any remaining issues with a planned trial for its Oxycyte drug.

Oxycyte is a perfluorocarbon oxygen carrier. Its proposed use is to help with traumatic brain injury. Oxygen Bio and the country’s standards agency have tentatively set Oct. 20 as the date.

“At that meeting, we will be extensively prepared to resolve any remaining issues and concerns the FDA may have,” said company Chairman and CEO Chris J. Stern. “We view this as a positive development, as the agency has also offered to review the Company’s overall development plan. This may contribute to reducing regulatory risk at future stages such as Phase III.”

Trials would be in the Phase 2b stage. The company would conduct a multi-center, double-blind, placebo-controlled study of up to 300 patients. 200 patients will be allowed for enrollment